Druggability Technologies (DRGT) is a proprietary pharmaceutical product business dedicated to the development and commercialization of high-value pharmaceutical products that deliver measurable and meaningful improvement in clinical efficacy. This mission is enabled through the deployment of the Company's Super-API Technology that delivers substantial improvement in pharmacokinetics/pharmacodynamics/bioavailability resulting in high-value, proprietary products.

The proprietary high throughput (HT)  Super-API technology delivers highly significant improvement in solubility, permeability and kinetics with unique properties unattainable by traditional approaches and provides a basis for creating novel relative New Chemical Entities (rNCEs) with the opportunity to file new intellectual property.

DRGT not only applies its technology to compounds in development by BioPharma partners, but also to in-marketed drugs near or at the end of their proprietary life cycle creating an internal pipeline of rNCEs with improved clinical performance.